QRONO, INC
- UEI
- S8NSYCMSNF79
- Land
- 🇺🇸 Verenigde Staten · PITTSBURGH (152032194)
- Gewonnen opdrachten
- 11
- Totale contractwaarde
- 689 835 USD
- Eerste opdracht
- 29/11/2017
- Laatste opdracht
- 30/08/2023
Top 5 · Publieke aanbesteders
- Department of Health and Human Services - National Institutes of Health 🇺🇸 10 gewonnen opdrachten
- Department of Health and Human Services - Food and Drug Administration 🇺🇸 1 gewonnen opdrachten
QRONO, INC heeft 11 overheidsopdrachten gewonnen die op Tendervue zijn geindexeerd. Bekijk hieronder de volledige lijst van aanbestedingen, publieke aanbesteders, CPV/PSC-categorieen en gegunde bedragen aan QRONO, INC.
Active 2017-2023
2 buyers
11 contracts
Gunningen (11)
| Datum | Aanbesteder | Omschrijving | Bedrag | Procedure |
|---|---|---|---|---|
| 30/08/2023 | Department of Health and Human Services - National Institutes of Health | SCREENING FOR TOLEROGENIC ADJUVANTS TO ENHANCE ANTIGEN SPECIFIC IMMUNOTHERAPY FOR CELIAC DISEASE. | 599 945 USD | FIRM FIXED PRICE |
| 06/01/2022 | Department of Health and Human Services - National Institutes of Health | APC SPECIFIC MTOP INHIBITION POTENTIATES IMMUNE RESPONSE TO IIV IN ELDERLY RECIPIENTS. | 0 USD | FIRM FIXED PRICE |
| 25/01/2021 | Department of Health and Human Services - National Institutes of Health | FAILED TUBULIN INHIBITOR REFORMULATED AS LOCALIZED ADJUVANT THERAPY FOR HEAD AND NECK CANCER | -2 016 USD | COST PLUS FIXED FEE |
| 18/03/2020 | Department of Health and Human Services - National Institutes of Health | FAILED TUBULIN INHIBITOR REFORMULATED AS LOCALIZED ADJUVANT THERAPY FOR HEAD AND NECK CANCER | 0 USD | COST PLUS FIXED FEE |
| 23/12/2019 | Department of Health and Human Services - National Institutes of Health | FAILED TUBULIN INHIBITOR REFORMULATED AS LOCALIZED ADJUVANT THERAPY FOR HEAD AND NECK CANCER | 0 USD | COST PLUS FIXED FEE |
| 27/09/2019 | Department of Health and Human Services - National Institutes of Health | FAILED TUBULIN INHIBITOR REFORMULATED AS LOCALIZED ADJUVANT THERAPY FOR HEAD AND NECK CANCER | 0 USD | COST PLUS FIXED FEE |
| 13/02/2019 | Department of Health and Human Services - National Institutes of Health | IGF::OT::IGF FAILED TUBULIN INHIBITOR REFORMULATED AS LOCALIZED ADJUVANT THERAPY FOR HEAD AND NECK CANCER | 0 USD | COST PLUS FIXED FEE |
| 25/07/2018 | Department of Health and Human Services - National Institutes of Health | IGF::OT::IGF FAILED TUBULIN INHIBITOR REFORMULATED AS LOCALIZED ADJUVANT THERAPY FOR HEAD AND NECK CANCER | 0 USD | COST PLUS FIXED FEE |
| 31/05/2018 | Department of Health and Human Services - Food and Drug Administration | IGF::CL::IGF BAA CONTRACT TITLED, "COMPUTATIONAL DRUG DELIVERY: LEVERAGING PREDICTIVE MODELS TO DEVELOP BIOEQUIVALENT GENERIC LONG-ACTING INJECTIONS." | 91 906 USD | COST PLUS FIXED FEE |
| 07/12/2017 | Department of Health and Human Services - National Institutes of Health | IGF::OT::IGF FAILED TUBULIN INHIBITOR REFORMULATED AS LOCALIZED ADJUVANT THERAPY FOR HEAD AND NECK CANCER | 0 USD | COST PLUS FIXED FEE |
| 29/11/2017 | Department of Health and Human Services - National Institutes of Health | IGF::OT::IGF FAILED TUBULIN INHIBITOR REFORMULATED AS LOCALIZED ADJUVANT THERAPY FOR HEAD AND NECK CANCER | 0 USD | COST PLUS FIXED FEE |
Bekijk de officiele bron (DECP - data.economie.gouv.fr) (USAS)